

SEQUENCE LISTING

EPO - DG 1

01. 07. 2004

(76)

5 <110> Santaris Pharma A/S
Elmén, Joacim
Wahlestedt, Claes
Liang, Zicai
Sørensen, Anders Malling
Ørum, Henrik
Koch, Troels

10 <120> Short interfering RNA (siRNA) analogues

15 <130> 34638PC01

<140> PCT/DK204/000192
<141> 2004-03-22

20 <150> DKPA200300442
<151> 2003-03-21

<150> DKPA200301625
<151> 2003-10-31

25 <150> DKPA200400145
<151> 2004-01-30

<160> 18

30 <170> FastSEQ for Windows Version 4.0

<210> 1
<211> 21
<212> RNA

35 <213> Artificial Sequence

<220>
<223> Short interfering (siRNA) analogues comprising LNA
monomers

40 <400> 1
cuuacgcuga guacuucgat t

45 <210> 2
<211> 21
<212> RNA
<213> Artificial Sequence

50 <220>
<223> Short interfering (siRNA) analogues comprising LNA
monomers

55 <400> 2
ucgaaguacu cagcguaagt t

<210> 3
<211> 21

21

21

2/4

<212> RNA
<213> Artificial Sequence

<220>
5 <223> Short interfering (siRNA) analogues comprising LNA
monomers

<400> 3
10 ugagagaaag cacagaaaat t 21

<210> 4
<211> 21
<212> RNA
<213> Artificial Sequence

15 <220>
<223> Short interfering (siRNA) analogues comprising LNA
monomers

20 <400> 4
uuuucugugc uuucucucat t 21

<210> 5
<211> 21

25 <212> RNA
<213> Artificial Sequence

<220>
30 <223> Short interfering (siRNA) analogues comprising LNA
monomers

<400> 5
aucugaagaa ggagaaaaat t 21

35 <210> 6
<211> 21
<212> RNA
<213> Artificial Sequence

40 <220>
<223> Short interfering (siRNA) analogues comprising LNA
monomers

<400> 6
45 uuuuucuccu ucuucagaut t 21

<210> 7
<211> 29
<212> DNA

50 <213> Artificial Sequence

<220>
<223> SARS 3 target DNA oligo with Xba I overhang

55 <400> 7
ctagcaaact gtcaaaccgc gtaattttc 29

<210> 8
<211> 29

3/4

<212> DNA
<213> Artificial Sequence

<220>
5 <223> SARS 3 target DNA oligo with Xba I overhang

<400> 8
gtttgacagt ttgggccatt aaaaggatc 29

10 <210> 9
<211> 21
<212> RNA
<213> Artificial Sequence

15 <220>
<223> siRNA targeting SARS

<400> 9
20 ggaugaggaa ggcaauuuat t 21

<210> 10
<211> 21
<212> RNA
<213> Artificial Sequence

25 <220>
<223> siRNA targeting SARS

<400> 10
30 ttccuacucc uuccguuaaa u 21

<210> 11
<211> 21
<212> RNA
35 <213> Artificial Sequence

<220>
<223> siRNA targeting SARS

40 <400> 11
cugguacgau uucggugaut t 21

<210> 12
<211> 21
45 <212> RNA
<213> Artificial Sequence

<220>
<223> siRNA targeting SARS

50 <400> 12
ttgaccaugc uaaagccacu a 21

<210> 13
55 <211> 21
<212> RNA
<213> Artificial Sequence

<220>

4/4

<223> siRNA targeting SARS

<400> 13
5 acugucaaaac ccgguaauut t 21

<210> 14
<211> 21
<212> RNA
<213> Artificial Sequence

10 <220>
<223> siRNA targeting SARS

<400> 14
15 ttugacaguu ugggccauua a 21

<210> 15
<211> 21
<212> RNA
20 <213> Artificial Sequence

<220>
<223> siRNA targeting SARS

25 <400> 15
gacaacuccu auucguagut t 21

<210> 16
<211> 21
30 <212> RNA
<213> Artificial Sequence

<220>
<223> siRNA targeting SARS

35 <400> 16
ttcuguugag gauaagcauc a 21

<210> 17
40 <211> 21
<212> RNA
<213> Artificial Sequence

<220>
45 <223> siRNA targeting SARS

<400> 17
cuuacgcuga guacuucgat t 21

50 <210> 18
<211> 21
<212> RNA
<213> Artificial Sequence

55 <220>
<223> siRNA targeting SARS

<400> 18
ttgaaugcga cucaugaagc u 21